Anti-Hypertensive Drugs - Israel

Israel

The Anti-Hypertensive Drugs market in Israel is expected to experience significant growth in the coming years.
According to projections, the market's revenue is set to reach US$61.44m in 2024.
Furthermore, the market is expected to exhibit a steady annual growth rate of -0.08% between 2024 and 2029.
This growth will lead to a market volume of US$61.20m by 2029.
When comparing Israel's Anti-Hypertensive Drugs market to the global landscape, it is important to note that United States will generate the highest revenue.
In 2024 alone, United States is expected to generate a staggering US$12,290.00m in revenue.
In Israel, the market for anti-hypertensive drugs is witnessing a significant rise due to the increasing prevalence of hypertension among the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Israel has been experiencing steady growth in recent years.

Customer preferences: The preference for Anti-Hypertensive Drugs in Israel is driven by the high prevalence of hypertension among the population. The aging population is also a significant factor as the risk of hypertension increases with age. Patients in Israel prefer to use drugs that are effective in controlling blood pressure, have minimal side effects, and are affordable.

Trends in the market: The Anti-Hypertensive Drugs market in Israel is witnessing a shift towards combination therapies. Combination therapies are more effective in controlling blood pressure than monotherapy. Patients in Israel are also increasingly using generic drugs, which are more affordable than branded drugs. The use of digital health technology to monitor blood pressure is also gaining popularity in Israel.

Local special circumstances: Israel has a universal healthcare system that provides coverage for Anti-Hypertensive Drugs. The government regulates drug prices, which has led to lower drug prices in Israel compared to other developed countries. The government also encourages the use of generic drugs to reduce healthcare costs.

Underlying macroeconomic factors: The Israeli economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The aging population in Israel is also contributing to the growth of the Anti-Hypertensive Drugs market. The government's focus on preventive healthcare and the use of digital health technology is expected to drive the growth of the Anti-Hypertensive Drugs market in Israel in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.